-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, BY0sjbHH4zNm3mNcbk1BWTXWpyH8hdgALOFdBWGaO+X5uFO/QHV81O4lBuhRICL0 h/ukQq7rQILznm5wM++iMQ== 0001014739-10-000015.txt : 20100623 0001014739-10-000015.hdr.sgml : 20100623 20100623095146 ACCESSION NUMBER: 0001014739-10-000015 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20100617 ITEM INFORMATION: Entry into a Material Definitive Agreement FILED AS OF DATE: 20100623 DATE AS OF CHANGE: 20100623 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BioScrip, Inc. CENTRAL INDEX KEY: 0001014739 STANDARD INDUSTRIAL CLASSIFICATION: RETAIL-DRUG STORES AND PROPRIETARY STORES [5912] IRS NUMBER: 050489664 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-28740 FILM NUMBER: 10911857 BUSINESS ADDRESS: STREET 1: 100 CLEARBROOK ROAD CITY: ELMSFORD STATE: NY ZIP: 10523 BUSINESS PHONE: 914 460 1600 MAIL ADDRESS: STREET 1: 100 CLEARBROOK ROAD CITY: ELMSFORD STATE: NY ZIP: 10523 FORMER COMPANY: FORMER CONFORMED NAME: MIM CORP DATE OF NAME CHANGE: 19960516 8-K 1 abdcform8k.htm ABDC AMENDMENT abdcform8k.htm
 
 


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 

FORM 8-K
 

 
CURRENT REPORT
 
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported) June 17, 2010
 

 
BIOSCRIP, INC.
(Exact name of Registrant as specified in its charter)


 
         
Delaware
  
0-28740
  
05-0489664
(State of Incorporation)
  
(Commission File Number)
  
(I.R.S. Employer
Identification No.)

 
     
100 Clearbrook Road, Elmsford, New York
  
10523
(Address of principal executive offices)
  
(Zip Code)

 
Registrant’s telephone number, including area code: (914) 460-1600
 
 
(Former name or former address, if changed since last report)
 

 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
¨
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 
¨
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 
¨
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 
¨
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 




 
 
 






Item 1.01                      Entry into a Material Definitive Agreement.

On June 17, 2010, BioScrip, Inc. (the “Company”) entered into the Second Amendment to the Prime Vendor Agreement (the “Second Amendment”), dated as of June 1, 2010, by and among AmerisourceBergen Drug Corporation, a Delaware corporation (“ABDC”) and the Company and each of its subsidiaries (as amended, the “Agreement”).

The Second Amendment (i) adds as parties to the Agreement subsidiaries acquired by the Company as part of its acquisition of Critical Homecare Solutions, Inc. and its subsidiaries, (ii) modifies certain terms associated with certain monthly net purchasing volumes and (iii) extends the termination date under the Agreement from August 31, 2012 to December 31, 2014.


 
2
 






SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
         
   
BIOSCRIP, INC.
     
     
     
Date: June    23 , 2010
      
/s/ Barry A. Posner
   
By:
  
Barry A. Posner
       
Executive Vice President, Secretary and General Counsel


 
3
 

-----END PRIVACY-ENHANCED MESSAGE-----